The results of Genome Enhancer analysis, contained in any of the reports produced by this pipeline, are
intended for research use only and should not be used for medical or professional advice. GeneXplain GmbH
makes no guarantee of the comprehensiveness, reliability or accuracy of the information contained in the
reports generated by Genome Enhancer.
Decisions regarding care and treatment of patients should be fully made by attending doctors. The predicted
chemical compounds listed in the reports are given only for doctor’s consideration and they cannot be
treated as prescribed medication. It is the physician’s responsibility to independently decide whether any,
none or all of the predicted compounds can be used solely or in combination for patient treatment purposes,
taking into account all applicable information regarding FDA prescribing recommendations for any therapeutic
and the patient’s condition, including, but not limited to, the patient’s and family’s medical history,
physical examinations, information from various diagnostic tests, and patient preferences in accordance with
the current standard of care. Whether or not a particular patient will benefit from a selected therapy is
based on many factors and can vary significantly.
The compounds predicted to be active against the identified drug targets in the reports are not guaranteed to
be active against any particular patient’s condition. GeneXplain GmbH does not give any assurances or
guarantees regarding the treatment information and conclusions given in the reports. There is no guarantee
that any third party will provide a refund for any of the treatment decisions made based on these results.
None of the listed compounds was checked by Genome Enhancer for adverse side-effects or even toxic effects.
The analysis reports contain information about chemical drug compounds, clinical trials and disease
biomarkers retrieved from the HumanPSD™ database of gene-disease assignments maintained and exclusively
distributed worldwide by geneXplain GmbH. The information contained in this database is collected from
scientific literature and public clinical trials resources. It is updated to the best of geneXplain’s
knowledge however we do not guarantee completeness and reliability of this information leaving the final
checkup and consideration of the predicted therapies to the medical doctor. In all cases, the end user
(including researchers and medical doctors) accepts full responsibility for all risks associated with using
of information, contained in the reports generated by Genome Enhancer.
The scientific analysis underlying the Genome Enhancer reports employs a complex analysis pipeline which uses
geneXplain’s proprietary Upstream Analysis approach, integrated with TRANSFAC® and TRANSPATH® databases
maintained and exclusively distributed worldwide by geneXplain GmbH. The pipeline and the databases are
updated to the best of geneXplain’s knowledge and belief, however, geneXplain GmbH shall not give a warranty
as to the characteristics or to the content and any of the results produced by Genome Enhancer. Moreover,
any warranty concerning the completeness, up-to-dateness, correctness and usability of Genome Enhancer
information and results produced by it, shall be excluded.
The results produced by Genome Enhancer, including the analysis reports, severely depend on the quality of
input data used for the analysis. It is the responsibility of Genome Enhancer users to check the input data
quality and parameters used for running the Genome Enhancer pipeline.
Note that the text given in the reports is not unique and can be fully or partially repeated in other Genome
Enhancer analysis reports, including reports of other users. This should be considered when publishing any
results or excerpts from the reports. This restriction refers only to the general description of analysis
methods used for generating the reports. All data and graphics referring to the concrete set of input data,
including lists of mutated genes, differentially expressed genes/proteins/metabolites, functional
classifications, identified transcription factors and master regulators, constructed molecular networks,
lists of chemical compounds and reconstructed model of molecular mechanisms of the studied pathology are
unique in respect to the used input data set and Genome Enhancer pipeline parameters used for the current
run.
